BamSEC and AlphaSense Join Forces
Learn More

Spyre Therapeutics Inc.

NASDAQ: SYRE    
Share price (10/4/24): $29.15    
Market cap (10/4/24): $1.481 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.7
from 10-Q 5 pages Notice of Restricted Stock Unit Award Spyre Therapeutics, Inc. 2018 Equity Inducement Plan
12/34/56
EX-10.6
from 10-Q 5 pages Notice of Stock Option Grant Spyre Therapeutics, Inc. 2016 Equity Incentive Plan
12/34/56
EX-10.5
from 10-Q 31 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Second Amended and Restated Antibody Discovery and Option Agreement
12/34/56
EX-10.4
from 10-Q 46 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. License Agreement
12/34/56
EX-10.3
from 10-Q 44 pages [***] = Certain Confidential Information Contained in This Document, Marked by Brackets, Has Been Omitted Because the Information (I) Is Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. License Agreement
12/34/56
EX-10.6
from 10-Q 4 pages Amendment No. 1 to the Novation Agreement
12/34/56
EX-10.1
from 8-K 7 pages April 23, 2024 Spyre Therapeutics, Inc. 221 Crescent St., Building 23, Unit 105 Waltham, Ma 02453 Attention: Scott Burrows Re: 3(a)(9) Exchange Agreement Ladies and Gentlemen
12/34/56
EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 68 pages Securities Purchase Agreement
12/34/56
EX-10.20
from S-1/A 9 pages Consulting Agreement
12/34/56
EX-10.19
from S-1/A 15 pages August 18, 2023 Heidy King-Jones Re: Offer of Employment Dear Heidy: On Behalf of Aeglea Biotherapeutics, Inc. (The “Company”), I Am Very Pleased to Offer You a Position as Chief Legal Officer and Corporate Secretary (The “Role”) Pursuant to This Letter Agreement (The “Agreement”), Provided You Accept Such Offer as Indicated by Your Signature Below
12/34/56
EX-10.8
from S-1/A 11 pages Spyre Therapeutics, Inc. 2016 Employee Stock Purchase Plan
12/34/56
EX-10.20
from 10-K 9 pages Consulting Agreement
12/34/56
EX-10.19
from 10-K 11 pages August 18, 2023 Heidy King-Jones
12/34/56
EX-10.4
from 10-K 10 pages Spyre Therapeutics, Inc. 2016 Employee Stock Purchase Plan
12/34/56
EX-10.19
from S-1/A 10 pages Indemnification Agreement
12/34/56
EX-10.4
from S-1/A 15 pages November 22, 2023 Cameron Turtle Re: Amended and Restated Employment Letter Agreement Dear Cameron
12/34/56
EX-10.2
from 8-K 1 page February 1, 2024 Cameron Turtle Re: Amendment to Amended and Restated Employment Letter Agreement Dear Cameron: This Letter, Effective as of the Date First Set Forth Above (This “Amendment”), Amends That Certain Amended and Restated Employment Letter Agreement Between You and Spyre Therapeutics, Inc. (F/K/a Aeglea Biotherapeutics, Inc.) (The “Company”) Dated November 22, 2023 (The “Agreement”). Section 11(a) of the Agreement Is Hereby Amended and Restated in Its Entirety as Set Forth Below
12/34/56
EX-10.1
from 8-K 10 pages Indemnification Agreement
12/34/56
EX-10.18
from S-1 9 pages Lease Termination Agreement
12/34/56